SPHS Sophiris Bio Inc.

0.54
0  0%
Previous Close 0.54
Open 0.6
Price To Book -7.71
Market Cap 19,197,256
Shares 35,550,474
Volume 57,107
Short Ratio
Av. Daily Volume 145,455
Stock charts supplied by TradingView

NewsSee all news

  1. Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ:SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

  2. Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

  3. Sophiris Bio Announces $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ:SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ:SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

  2. Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

  3. Sophiris Bio Announces $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ:SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a